BioPorto Logo

BioPorto

An in vitro diagnostics company specializing in biomarkers for early kidney injury detection.

BIOPOR | CO

Overview

Corporate Details

ISIN(s):
DK0011048619
LEI:
5299004SWFL5JAN4W830
Country:
Denmark
Address:
Tuborg Havnevej 15, st., 2900 Hellerup

Description

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-24 10:37 Danish 34.3 KB
2025-11-24 10:37 English 32.7 KB
2025-11-24 10:37 Danish 566.4 KB
2025-11-24 10:37 English 527.4 KB
2025-11-24 10:09 English 7.4 KB
2025-11-24 10:09 Danish 520.8 KB
2025-11-24 10:09 Danish 7.4 KB
2025-11-24 10:09 English 500.5 KB
2025-11-13 19:50 English 12.3 KB
2025-11-13 19:50 Danish 545.9 KB
2025-11-13 19:50 English 511.2 KB
2025-11-13 19:50 Danish 12.2 KB
2025-11-04 22:10 Danish 225.4 KB
2025-11-04 22:10 English 238.1 KB
2025-11-04 22:10 English 18.9 KB

Automate Your Workflow. Get a real-time feed of all BioPorto filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioPorto

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioPorto via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ARTELO BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing therapeutics by modulating the endocannabinoid system.
United States of America
ARTL
Ascelia Pharma Logo
Biotechnology company developing and commercializing novel drugs for orphan oncology.
Sweden
ACE
Ascendis Pharma A/S Logo
Biopharmaceutical firm using its prodrug technology to treat rare diseases.
United States of America
ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
A clinical-stage biopharma developing novel therapies for cancer and other diseases.
United States of America
AAPG
Specializes in hormone-related pharmaceuticals for internal medicine, OB/GYN, and urology.
Japan
4886
Aspire Biopharma Holdings, Inc. Logo
Develops sublingual drug delivery technologies for needle-free medications.
United States of America
ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
A clinical-stage biotech developing small molecule antiviral therapeutics for viral diseases.
United States of America
ASMB
Assertio Holdings, Inc. Logo
Pharmaceutical company managing branded products for neurology and orphan diseases.
United States of America
ASRT
Astellas Pharma Inc. Logo
A global pharmaceutical company turning innovative science into value for patients.
Japan
4503
AstraZeneca PLC Logo
A global, science-led biopharmaceutical company developing prescription medicines.
United Kingdom
AZN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.